Monitor launch timeline and initial market share in Canada. The approval positions Dr. Reddy's to capture early generic GLP-1 demand, but pricing and competition dynamics will determine actual financial impact. Watch for updates on U.S. semaglutide approval status.
RDY drugs
RDY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $13.73entry
- T+1 · 7mo ago −0.66%α −1.68% · $13.64
- T+5 · 7mo ago −1.97%α −5.08% · $13.46
- T+20 · 6mo ago −1.53%α −7.58% · $13.52
- T+60 · 4mo ago −14.13%α −18.24% · $11.79
Price Chart
How similar events traded
Executive Summary
Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, the first generic semaglutide authorized in Canada. This expands the company's GLP-1 portfolio and strengthens its position in the global diabetes market, though no financial terms were disclosed.
Key Facts
- First generic semaglutide approved by Health Canada for type 2 diabetes
- Approval covers 2 mg/pen and 4 mg/pen strengths
- API produced in-house; finished product by OneSource Specialty Pharma
- Launch preparations are underway
- Canada is the second-largest market for semaglutide globally (IQVIA)
Financial Impact
Undisclosed; potential for material revenue contribution given Canada's large semaglutide market and first-to-market advantage
Risk Factors
- Competition from other generic entrants
- Pricing pressure from payers and branded discounts
- Manufacturing or supply constraints
- Regulatory delays in other markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000265 |
| Document: 0001575872-26-000265-index.html | 0001575872-26-000265 |
| Document: 0001575872-26-000265.txt | 0001575872-26-000265 |
Track record
73 reports on RDY
7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers